Verrica Pharmaceuticals Inc. · NASDAQ:VRCA

Verrica Pharmaceuticals — Investor Presentation (April 2020)

31 slides from Verrica Pharmaceuticals's investor presentation, April 2020

  1. Slide 1: Company Overview

    Company Overview April 2020 Copyright © 2020 Verrica Pharmaceuticals. All rights reserved.

  2. Slide 2: Disclaimer

    DISCLAIMER Certain information contained in this presentation and statements made orally during The information in this presentation, including without limitation the forward-looking this presentation relates to or is based on studies, publications, surveys and other data statements contained herein

  3. Slide 3: Developing novel dermatology products

    Providing meaningful benefit for people living Developing with skin diseases novel Reinventing dermatology Skin Science products by focusing on development and commercialization Late-stage dermatology therapeutics company Copyright © 2020 Verrica Pharmaceuticals. All rights reserved. 3 Copyright © 2

  4. Slide 4: Investment Highlights

    INVESTMENT HIGHLIGHTS Two of the Largest Unmet Needs in Dermatology Innovative Product Candidate • Prevalence of ~6 million in molluscum contagiosum(1) • Drug-device combination of a proprietary formulation and ~22 million in common warts in the U.S. (2) and a novel single-use applicator • No FDA ap

  5. Slide 5: Our Product Portfolio

    OUR PRODUCT PORTFOLIO NDA NEXT EXPECTED PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ACCEPTANCE MILESTONE YCANTH PDUFA Goal Date: Molluscum Contagiosum July 13, 2020 Initiate pivotal Phase 3 VP-102 Common Warts trials in 1H 2020 VP-102 Topline Phase 2 results in External Genital Warts 2H 2020 Initiate Phase

  6. Slide 6: Two of the Largest Unmet Needs in Dermatology

    TWO OF THE LARGEST UNMET NEEDS IN DERMATOLOGY Molluscum Common Warts US Prevalence of ~6 million(1) with US Prevalence of ~22 million(3) with ~1 million diagnosed annually(2) ~1.5 million diagnosed annually(4) 85% 22M Prevalence in U.S. Not Diagnosed 5.1 million 1.5M 15% Patients Diagnosed Annually

  7. Slide 7: The Problem: Molluscum Contagiosum

    THE PROBLEM Molluscum Contagiosum Copyright © 2020 Verrica Pharmaceuticals. All rights reserved.

  8. Slide 8: Molluscum Background

    MOLLUSCUM BACKGROUND OVERVIEW ETIOLOGY AND CLINICAL PRESENTATION Caused by a pox virus Transmission • Skin to skin contact • Sharing of contaminated objects (e.g., clothing, towels, Primarily infects children, with the swimming pool toys) highest incidence occurring in children <14 years old Diagnos

  9. Slide 9: Current Treatments for Molluscum

    CURRENT DESCRIPTION LIMITATIONS TREATMENTS FOR MOLLUSCUM Cryotherapy Freezing the lesions with liquid nitrogen • Pain and scarring ARE NOT FDA • Unsuitable for use in children APPROVED AND Curettage Using a curette or a surgical instrument with a scoop at • Pain and scarring HAVE MANY the tip to scr

  10. Slide 10: The Solution: Ycanth (VP-102)

    THE SOLUTION YCANTH™ (VP-102) Copyright © 2020 Verrica Pharmaceuticals. All rights reserved.

  11. Slide 11: Ycanth (VP-102) Drug-Device Combination with Single-Use Applicator

    YCANTH™ (VP-102) IS A PROPRIETARY DRUG-DEVICE COMBINATION OF CANTHARIDIN ADMINISTERED THROUGH OUR SINGLE-USE PRECISION APPLICATOR GMP-controlled new formulation of 0.7% w/v cantharidin • Consistent and shelf-stable Filter Ampule Tube Cap Tip Single-use applicator to reduce cross-contamination and al

  12. Slide 12: Molluscum Clinical Evidence

    Molluscum Clinical Evidence Copyright © 2020 Verrica Pharmaceuticals. All rights reserved.

  13. Slide 13: Two Pivotal Phase 3 Trials (CAMP-1 & CAMP-2) Completed

    WE HAVE SUCCESSFULLY COMPLETED TWO PIVOTAL PHASE 3 TRIALS (CAMP-1 & CAMP-2) IN MOLLUSCUM Two identically designed, randomized, CAMP-1 conducted under 12-week Trial Design double-blinded, multicenter, placebo FDA Special Protocol study period controlled trials Assessment (SPA) Primary: Secondary: End

  14. Slide 14: Phase 3 Efficacy on Complete Clearance

    PHASE 3 STUDIES IN MOLLUSCUM DEMONSTRATE STATISTICALLY SIGNIFICANT EFFICACY ON PRIMARY ENDPOINT OF COMPLETE CLEARANCE 14 Copyright © 2020 Verrica Pharmaceuticals. All rights reserved. Note: Slide reflects pooled data from Phase 3 molluscum trials (CAMP-1 and CAMP-2)

  15. Slide 15: Phase 3 Efficacy on Percent Reduction of Lesions

    PHASE 3 STUDIES IN MOLLUSCUM DEMONSTRATE STATISTICALLY SIGNIFICANT EFFICACY ON PERCENT REDUCTION OF LESIONS 15 Copyright © 2020 Verrica Pharmaceuticals. All rights reserved. Note: Slide reflects pooled data from Phase 3 molluscum trials (CAMP-1 and CAMP-2)

  16. Slide 16: Phase 3 Discontinuation Rates Due to Adverse Events

    PHASE 3 DISCONTINUATION RATES DUE TO TREATMENT-RELATED ADVERSE EVENTS N (%) VP-102 Vehicle (N=311) (N=216) Application Site Vesicles 5 (1.6) 0 (0) Application Site Pain 3 (1.0) 0 (0) Application Site Pruritus 1 (0.3) 0 (0) Contact Dermatitis 1 (0.3) 0 (0) Total Discontinuation Rate 6 (1.9) 0 (0) 16

  17. Slide 17: MC Commercial Opportunity

    MC Commercial Opportunity Copyright © 2020 Verrica Pharmaceuticals. All rights reserved.

  18. Slide 18: Realizing the Molluscum Opportunity

    REALIZING THE MOLLUSCUM OPPORTUNITY US Prevalence of ~6 million in molluscum(1) with ~1 million diagnosed annually(2) 85% Not Diagnosed 5.1 million 15% Diagnosed (1) Prevalence in the US of 5.1% to 11.5% in children aged 0-16 years. (Fam Pract. 2014 Apr;31(2):130-6). US Census estimates 0.9 million

  19. Slide 19: Dermatologists Familiar with API Used in Ycanth

    DERMATOLOGISTS ARE FAMILIAR WITH API USED IN YCANTH™ (VP-102) & WOULD USE IF AVAILABLE ~70% 87% Physicians who do not use the API of Physicians reported they Ycanth™ (VP-102) stated inaccessibility as a would use Ycanth™ (VP-102) if the primary reason why they are not using(1) cost of the drug was c

  20. Slide 20: Physicians Highly Favorable to Ycanth Profile

    PHYSICIANS ARE HIGHLY FAVORABLE TO YCANTH (VP-102) PROFILE Derms and Ped Derms (1) KEY REASONS TO USE IF APPROVED 5.6 Efficacy Precise and pain free application FDA approval Convenience of administration Pediatricians (1) KEY REASONS TO USE IF APPROVED 6.3 Efficacy Fits into their current office mod

  21. Slide 21: Initial Payer Research Suggests Favorable Reimbursement

    INITIAL PAYER RESEARCH SUGGESTS FAVORABLE REIMBURSEMENT LANDSCAPE FOR YCANTH™ (VP-102) COHORT SIZE AVERAGE LIVES COVERED The 15 Payer Organizations and Medical Plans Represented in the Interviews Directors 7 9.8M Cover a Total of 105 Million Commercial & Medicaid Lives Pharmacy Directors 6 4.2M IDN

  22. Slide 22: Payer Research Key Takeaways

    INITIAL PAYER RESEARCH SUGGESTS FAVORABLE REIMBURSEMENT LANDSCAPE FOR YCANTH™ (VP-102) Key Takeaways 1 Payers interviewed recognize a significant unmet need for molluscum contagiosum and lack of an effective treatment 2 Some of the key concerns mentioned about the undertreatment of the condition inc

  23. Slide 23: Integrated Commercial Approach with Multiple Strategic Levers

    INTEGRATED COMMERCIAL APPROACH WITH MULTIPLE STRATEGIC LEVERS Commercial Strategy KOL Buy and Bill Specialized Dedicated Disease Engagement or Specialty Sales Team Institutional Awareness Strong Pharmacy Targeting Team Increase established Distribution office based Specialists to treatment seekers r

  24. Slide 24: Several Potential Ways to Maintain Exclusivity

    VERRICA HAS SEVERAL POTENTIAL WAYS TO MAINTAIN EXCLUSIVITY Regulatory 5.5 years of exclusivity for cantharidin as API potentially available upon approval Exclusivity (inclusive of potential for 6 months for pediatric indication) If VP-102 is approved, traditional compounding pharmacies The FDA has t

  25. Slide 25: Overview of Intellectual Property Portfolio

    OVERVIEW OF INTELLECTUAL PROPERTY PORTFOLIO KEY CLAIMS AND PATENT APPLICATIONS VALUE TO VERRICA Our specific formulation, Ycanth™ (VP-102), key safety May prevent generics from copying our ether-free formulation or from additions and novel cantharidin formulations making similar formulations (PCT/US

  26. Slide 26: Our Opportunity in Common Warts

    Our Opportunity in Common Warts Copyright © 2020 Verrica Pharmaceuticals. All rights reserved.

  27. Slide 27: Verruca Vulgaris (Common Warts)

    VERRUCA VULGARIS (COMMON WARTS) OVERVIEW ETIOLOGY AND CLINICAL PRESENTATION Caused by human papilloma virus Transmission • Skin to skin contact (HPV) • Touching of contaminated objects Infects patients of all ages Diagnosis • Dome shaped flesh-colored lesions commonly & Symptoms on the hands, finger

  28. Slide 28: Phase 2 Study (COVE-1) in Common Warts

    WE HAVE SUCCESSFULLY COMPLETED A PHASE 2 STUDY (COVE-1) IN COMMON WARTS Cohort 1: one center Study Design Efficacy, safety & tolerability Open label study with two cohorts Cohort 2: four centers Secondary Primary Percent of subjects achieving complete clearance Endpoints Percent of subjects with com

  29. Slide 29: VP-102 Efficacy on Complete Clearance in COVE-1

    VP-102 DEMONSTRATED CLINICALLY MEANINGFUL EFFICACY ON PRIMARY ENDPOINT OF COMPLETE CLEARANCE IN COVE-1 STUDY 29 Copyright © 2020 Verrica Pharmaceuticals. All rights reserved.

  30. Slide 30: Discontinuation Rates for COVE-1

    DISCONTINUATION RATES FOR COVE-1 Cohort 1 Cohort 2 VP-102 VP-102 (N=21) (N=35) Discontinued (total, N(%)) 4 (19.0%) 2 (5.7%) Lost to follow-up 2 (9.5%) 1 (2.9%) Withdrawal by subject 2 (9.5%) 0 Protocol violation 0 1 (2.9%) Copyright © 2020 Verrica Pharmaceuticals. All rights reserved.

  31. Slide 31: Significant Recent and Expected Milestones

    SIGNIFICANT RECENT AND EXPECTED MILESTONES DATE EVENT 1Q 2019 Positive topline results from two pivotal Phase 3 trials in molluscum 2Q 2019 Positive topline results from Phase 2 trial in common warts 2Q 2019 Initiate Phase 2 trial in external genital warts 3Q 2019 Ycanth™ (VP-102) NDA submission in

Verrica Pharmaceuticals — Investor Presentation (April 2020) on 6ix